Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
A phase 1/2 trial of Saruparib in advanced solid tumours, run by AstraZeneca, now recruiting.
Overview
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours is a phase 1/2 interventional study registered as NCT07446855 by AstraZeneca, with 180 participants planned, started 2026-03-17 and due to reach its primary completion in 2030-03-29. Interventions recorded: AZD4956 and Saruparib.
Similar pages
not linked directly; found by shared links- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.